Divi's Laboratories posted a 17% rise in consolidated net profit to Rs 606 crores in Q2 FY22 from Rs 520 crore posted in the corresponding quarter last year.
The drug major reported a 13.6% increase in revenue from operations to Rs 1,987.51 crore in Q2 FY22 from Rs 1749.30 posted in Q2 FY21. Profit before Tax (PBT) for the quarter amounted to Rs 760 crore in Q2 FY22, 9.6% higher than Rs 693 crore registered in Q2 FY21.The company said it continues to have near normal operations in the quarter complying with all Covid-19 protocols.
Divis Laboratories is the leading manufacturer of APIs (Active Pharmaceuticals Ingredients), intermediates and registered starting materials offering high quality products with the highest level of compliance and integrity to over 95 countries.
Shares of Divi's Laboratories ended 1.17% higher at Rs 5,205.05 in the special one-hour Muhurat trading session on Thursday, 4 November 2021.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
